- $1.01bn
- $1.78bn
- $894.66m
Annual income statement for Neogen, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 468 | 527 | 822 | 924 | 895 |
| Cost of Revenue | |||||
| Gross Profit | 215 | 243 | 406 | 464 | 421 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 394 | 469 | 785 | 866 | 1,956 |
| Operating Profit | 74.2 | 58.6 | 37.5 | 58.7 | -1,061 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 75.3 | 60.2 | -22 | -14.3 | -1,133 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 60.9 | 48.3 | -22.9 | -9.42 | -1,092 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 60.9 | 48.3 | -22.9 | -9.42 | -1,092 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 60.9 | 48.3 | -22.9 | -9.42 | -1,092 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.568 | 0.447 | 0.115 | 0.039 | -1.83 |